Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In Reply We thank the authors for their appraisal of our recent article and wish to expand on a few aspects.
An important point raised by Canevelli and Blasimme is that of incidental findings, which are currently being generated in genome analyses without a clear perspective on how to implement them in clinical practice and patient counseling.1 Further illustrating the need to catch up with genetics2 is recent progress in pooled data analyses. For example, comprehensive online tools are available to view and (meta-)analyze available genetic data on Parkinson disease and Alzheimer disease (http://www.pdgene.org/ and http://www.alzgene.org). However, to make optimal use of this resource and to use it in clinical practice, we need to connect genetic and clinical information.
Kasten M, Grünewald A, Klein C. Next-Generation Phenotyping and Genomic Incidental Findings—Reply. JAMA Neurol. 2013;70(12):1590–1591. doi:10.1001/jamaneurol.2013.4812
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: